Effect of a Clinical Nutrition Intervention Program in Breast Cancer Patients During Antineoplastic Treatment
NCT03625635 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34
Last updated 2018-08-10
Summary
The aim of this study is to evaluate the effect of a 6-mo individualized and specialized food-based nutrition intervention program in breast cancer patients' body composition, metabolism and antioxidant activity associated with micronutrients, during antineoplastic treatment.
It is a quasi-experimental prospective follow-up study of women with primary diagnosis of invasive breast cancer in Sonora, Mexico. Conducted between September 2015 through July 2018. The Ethics and Research Committees of The Oncology State Centre and the Food and Development Research Centre, have approved the study's protocol and procedures. At baseline, all participants must sign an informed consent form and answer an oral interview, including self-reported questionnaires, for their nutrition record.
At the beginning and 6-mo after, participants will be weighed during the morning in a digital scale and height will be measured using a digital stadiometer. Body mass index (BMI) will be calculated and classified according to the World Health Organization criteria. Waist and hip circumferences will be measured with a metal tape, according to the protocol of the International Society for the Advancement of Kinanthropometry (ISAK), by a certified anthropometrist. Body composition components will be measured in a dual-energy x-ray absorptiometry (Hologic Corporation 4500 Waltham, MA) by total body, L1-L4, and femur neck scans. Blood samples will be drawn by a certified phlebotomist using sterile equipment and aseptic techniques.
Breast cancer patients' total energy expenditure will be estimated using an algorithm for Mexican population. Diet plans and recommendations will be based on the individual's nutritional status, dietary habits, symptoms and treatment side-effects, socioeconomic and cultural preferences; as well as the WCRF/AICR guidelines adapting 1.5g/kg/d of dietary protein to avoid sarcopenic obesity and considering a caloric restriction (500-1000 kcal/d), when required. The individualized nutrition intervention program will be based on the macronutrient meal-equivalent menu method, and standard food servings will be based on the Mexican Food Equivalent System. To guarantee that the obtained content for each macronutrient (g/day) meets the theoretical calculations, protein ±1g/d, total fat ±1g/d, carbohydrates ±2g/d and energy ±15 kcal/d variations will be accepted.
Breast cancer patients follow-up will be every 2-weeks and a different diet menu will be provided in each session by a specialized dietitian, unto 6-mo are completed, and initial measurements will be repeated. The differences in body composition determinants will be analyzed using paired Student's t-test analysis for each variable. A two-tailed P-value of 0.05 or less will be considered significant.
Retinol, tocopherol and carotenoids determination will be performed using HPLC. Serum will be thawed and retinol will be extracted using chloroform:methanol (3:1) and hexane, extracted layers will be combined and then evaporated to dryness under a soft stream of nitrogen. Samples will be re-suspended in ethanol before injecting onto the HPLC using a YMC C-30 column (30 cm length, 4.6 mm internal diameter, 3 µm particle size and 100 mm pore size). The HPLC system is an Agilent 1200 with UV-Vis and PDA detectors. Commercial standards and internal standards will be used to assess concentration and extraction efficiency, respectively. Additionally, the investigators will use a standard NIST serum (National Institute of Standards and Technology; Gaithersburg, Maryland USA). The cut-off point for vitamin A deficient status will be set at \< 1.05 μmol /L.
The plasma antioxidant capacity will be determined by the trolox-equivalent antioxidant capacity test (TEAC) and oxygen radical absorbance capacity assay (ORAC). For both assays, results will be expressed as millimoles of Trolox equivalents per liter. The effect and their interaction on the response variables will be determined by ANOVA. Tukey's test will be used for the comparison of the means. Values of p\<0.05 will be accepted as statistically significant.
Human inflammatory cytokines and chemokines will be analyzed by using a panel of 12 pro-inflammatory cytokines as a conventional ELISA protocol all at once under uniform conditions. The cytokines and chemokines represented by this array will be IL1A, IL1B, IL2, IL4, IL6, IL8, IL10, IL12, IL17A, IFNg, TNFa, and GM-CSF.
Plasma activities of both enzymes, glutathione peroxidase (GPx) and superoxide dismutase (SOD) will be determined in baseline samples and after 6-mo, by using an ELISA (enzyme-linked immunosorbent assay) based upon a sandwich assay principle and can be used to detect levels of SOD as low as 0.066 ng/mL and 1.56 ng/mL for GPx.
Conditions
- Breast Neoplasm
- Breast Cancer
Interventions
- OTHER
-
Individualized food-based intervention
Diet plans and recommendations will be based on the individual's nutritional status, symptoms and treatment side-effects, socioeconomic and cultural preferences; as well as the WCRF/AICR guidelines adapting 1.5g/kg/d of dietary protein and when required, a caloric restriction (500-1000 kcal/d). Garlic and cruciferous vegetables will be encouraged as well as 5-9 servings of fruits and vegetables a day. The program will be based on the macronutrient meal-equivalent menu method, and standard food servings will be based on the Mexican Food Equivalent System. Breast cancer patients follow-up will be every 2-weeks and a different diet menu will be provided in each session by a specialized dietitian, unto 6-mo are completed.
Sponsors & Collaborators
-
Humberto Francisco Astiazaran Garcia, PhD
lead OTHER
Principal Investigators
-
Humberto Astiazaran-Garcia, PhD · Centro de Investigacion en Alimentacion y Desarrollo (CIAD)
Study Design
- Allocation
- NA
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-09-14
- Primary Completion
- 2018-09-30
- Completion
- 2019-08-31
Countries
- Mexico
Study Locations
More Related Trials
-
Antioxidant Supplements, Genetics and Chemotherapy Outcomes
NCT03413761 ·Status: COMPLETED
-
Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer
NCT05025059 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Percent Weight Change in the Medical Supplement Group of Early Breast Cancer
NCT06311357 ·Status: RECRUITING ·Phase: NA
-
Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors
NCT03953157 ·Status: COMPLETED ·Phase: NA
-
Interactive Care Plan for the Monitoring of Symptoms and Recovery in Patients With Stage 0-III Breast Cancer
NCT04693338 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Short-term Fasting on Tolerance to Chemotherapy
NCT01304251 ·Status: COMPLETED ·Phase: NA
-
The Anti-tumor Effect of Metformin And Atorvastatin in Breast Cancer
NCT05507398 ·Status: UNKNOWN ·Phase: PHASE4
-
Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer
NCT00463489 ·Status: COMPLETED ·Phase: NA
-
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer
NCT01594398 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors
NCT01758146 ·Status: UNKNOWN ·Phase: PHASE3
-
Exercise in Older Women With Breast Cancer During Systemic Therapy
NCT03656731 ·Status: COMPLETED ·Phase: NA
-
Supervised Aerobic Training During or After Chemotherapy for Operable Breast Cancer
NCT01943695 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer
NCT01298362 ·Status: COMPLETED
-
Altering Lipids for Tolerance of Aromatase Inhibitor Therapy
NCT04268134 ·Status: COMPLETED ·Phase: PHASE2
-
Examining the Relationships Between Sleep, Fatigue, and Pain in Aromatase Inhibitor-treated Patients
NCT01983995 ·Status: COMPLETED
-
Effects Of Concentric Cycling Training Protocol During (Neo)Adjuvant Chemotherapy in Breast Cancer Patients: PROTECT-07 Study
NCT06455904 ·Status: RECRUITING ·Phase: NA
-
Evaluation of Eating Habits and Dysgeusia During Chemotherapy Treatment in Patients Affected by Breast Cancer
NCT03210441 ·Status: UNKNOWN
-
Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics
NCT00612560 ·Status: COMPLETED ·Phase: NA
-
Iodine Supplementation on Breast Cancer
NCT03688958 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of the Therapeutic Effect of Atorvastatin on the Clinical Outcomes in HER2 Negative Breast Cancer Patients"
NCT05103644 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Impact of a Food Supplement on Musculoskeletal Pain in Women With Breast Cancer Treated With Aromatase Inhibitors.
NCT07199556 ·Status: COMPLETED ·Phase: NA
-
Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk
NCT06557057 ·Status: RECRUITING
-
Symptom Monitoring Using Patient-Report to Improve Medication Use
NCT06765707 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Study of Statin as Neo-Adjuvant Therapy in Postmenopausal Breast Cancer
NCT00816244 ·Status: COMPLETED ·Phase: PHASE2
-
Exercise Training in Postmenopausal Patients With Breast Cancer
NCT01384838 ·Status: COMPLETED ·Phase: NA